RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

The study offers promising news for people with type 2 diabetes. By using SGLT2 inhibitors, they may be able to lower their ...

With respect to risks, GLP-1RA use was significantly associated with an increased risk of gastrointestinal disorders, hypotension, syncope, arthritic disorders, drug-induced pancreatitis, and other ...

The global diabetic nephropathy market was valued at $1.9 billion in 2021, and is projected to reach $3.3 billion by 2031, growing at a CAGR of 6%.

A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...

New research shows diabetes medication SGLT-2 inhibitors lower dementia risk by up to 35%, offering hope for millions ...

SGLT2 inhibitors significantly improves kidney health in a diverse group of Asian adults with Type 2 diabetes, study finds.

Learn how diabetes medications could revolutionize stroke prevention and enhance heart and brain health with breakthrough ...

Findings indicate that dapagliflozin and calorie restriction together improve weight loss and metabolic health, increasing ...

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.